Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know On April 15, 2026, the FDA announced a significant regulatory update: injectable GHK-Cu (copper tripeptide-1) will be removed from the Category 2 bulk substances list by July 2026
Smaller infarcts preserve more functional tissue, which translates to better pumping ability and improved long-term outcomes
Age verification (minimum 18 years) is required for all purchasers and institutions compliance must be confirmed before proceeding with orders.Research institutions must ensure that all personnel handling these compounds understand the research-only limitations and maintain proper documentation of compound use
This is always discussed during consultation
Serious reactions are rare and usually linked to poor-quality products or unsafe injection practices
This product is not intended to diagnose, treat, cure, or prevent any disease
